



이름: 전은정 /Eun Jung Jun

직위: 연구소장/Chief Medical Officer

소속: (주)도터/Dotter. Inc

기타소속: 연구소/Medical Center

**강연제목:** 신생 관상동맥 병변을 가진 환자에서 에베로리무스 약물방출 흡수성 관상동맥용 스텐트 BRS™ 과 XIENCE Sierra™ 의 안전성과 유효성을 비교 평가하기 위한 전향적, 다기관, 평행설계, 단일 눈가림, 무작위 배정, 확증 임상시험  
(A prospective, multicenter, parallel, single-blind, randomized, pivotal study to evaluate the safety and efficacy of the everolimus eluting bioresorbable stent 'BRS™' compared to 'XIENCE Sierra™' stent in patients with de novo coronary artery lesions.)

#### Abstract:

This study investigates the efficacy, clinical safety, and effectiveness of the everolimus drug-eluting bioresorbable coronary stent BRS™ in a randomized controlled trial designed to enable regulatory approval of this new device in South Korea. One hundred twenty-eight patients from 10 centers will be randomized to either the BRS™ group (n=64) or the reference XIENCE Sierra™ group (n=64). The indication is de novo coronary stenosis patients who need coronary stent procedures with a reference vessel diameter of more than 2.5mm and less than 3.75mm, and a lesion length of less than 19mm. The primary endpoint is angiographic in-segment late lumen loss at 12 months. Secondary endpoints are major adverse cardiovascular events composed of cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis at 12 months. In addition, optical coherence tomography imaging analysis will be analyzed at 36 months.

#### Brief Biosketch

Dr. Eun Jung Jun is currently a Chief Medical Officer at the Dotter. Inc since 2017. She is in charge of clinical trials in the Medical Center. She got her Ph.D. from the University of Ulsan College of Medicine in 2010. After that, she took the position of research professor at the Department of Radiology at Asan Medical Center and researched functional stent development.